G1 Therapeutics, Inc.
Our mission is to develop and deliver innovative therapies that improve the lives of adults living with cancer. G1 is currently commercializing the Company’s first FDA-approved product, COSELA™ (trilaciclib), designed to improve outcomes for adults with extensive-stage small-cell lung cancer who are receiving chemotherapy. G1 is also executing a tumor-agnostic development program evaluating COSELA in combination with multiple treatment types and across multiple tumor types, including colorectal, breast, and bladder cancers.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
No